Sort
51,593 grants matching “hepatitis”
Correlates of protective immunity to HCV and rational vaccine design: Project 3
$957,184Rama Rao Amara · Emory University · U19 · FY2023 · AI
Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis
$957,122Michael R Grever · Ohio State University · UM1 · FY2016 · CA
Therapeutic targets in African-American youth with type 2 diabetes
$956,924Stephanie Therese Chung · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Agonists of the RIG-I Innate Immune Pathway
$956,404Shawn Patrick Iadonato · Kineta, Inc. · R44 · FY2012 · AI
Pathogenesis Of Enteric Viral Hepatitis
$956,113Robert H. Purcell · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Biobehavioral Studies of Obesity, Weight loss and Recidivism
$955,976Ranganath Muniyappa · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
TLR4 and TGF-beta interactions in HCC induced by HCV and alcohol
$955,937Hidekazu Tsukamoto · University Of Southern California · RC2 · FY2010 · AA
Structural Biology Of Virus Assembly
$955,825Paul T Wingfield · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2021 · AR
Core D: Clinical Research Core
$955,583Ighovwerha Ofotokun · Emory University · P30 · FY2020 · AI
Building on Needle Exchange to Optimize HIV Prevention/Treatment
$955,194Gregory M Lucas · Johns Hopkins University · R01 · FY2017 · DA
Evolvable 'Resistance-Proof' Therapies
$955,000Leor S Weinberger · J. David Gladstone Institutes · DP1 · FY2017 · DE
Evolvable 'Resistance-Proof' Therapies
$955,000Leor S Weinberger · J. David Gladstone Institutes · DP1 · FY2014 · DE
Evolvable 'Resistance-Proof' Therapies
$955,000Leor S Weinberger · J. David Gladstone Institutes · DP1 · FY2016 · DE
Evolvable 'Resistance-Proof' Therapies
$955,000Leor S Weinberger · J. David Gladstone Institutes · DP1 · FY2015 · DE
GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV
$954,675Valerian Nakaar · Carogen Corporation · R44 · FY2022 · DK
Individual, Network and Spatial Drivers of HIV and HCV among PWID in India
$954,451Sunil Suhas Solomon · Johns Hopkins University · R01 · FY2018 · DA
Molecular Biology of Picornavirus Replication
$954,367Elvera Ehrenfeld · Niaid Extramural Activities · Z01 · FY2007 · AI
Non-invasive staging of Metastasis by Precision MRI
$954,220Jenny J Yang · Inlighta Biosciences, Llc · R44 · FY2022 · CA
Prevalence of PAH in SCD Patients in Nigeria
$954,218Mark Thomas Gladwin · National Heart, Lung, And Blood Institute · Z01 · FY2008 · HL
Phenotyping Genetic Disorders of Hepatic Lipid and Lipoprotein Metabolism in Cells, Mice, and Men
$953,882Henry N Ginsberg · Columbia University Health Sciences · R35 · FY2023 · HL
Phenotyping Genetic Disorders of Hepatic Lipid and Lipoprotein Metabolism in Cells, Mice, and Men
$953,882Henry N Ginsberg · Columbia University Health Sciences · R35 · FY2020 · HL
Phenotyping Genetic Disorders of Hepatic Lipid and Lipoprotein Metabolism in Cells, Mice, and Men
$953,882Henry N Ginsberg · Columbia University Health Sciences · R35 · FY2017 · HL
Phenotyping Genetic Disorders of Hepatic Lipid and Lipoprotein Metabolism in Cells, Mice, and Men
$953,882Henry N Ginsberg · Columbia University Health Sciences · R35 · FY2018 · HL
Phenotyping Genetic Disorders of Hepatic Lipid and Lipoprotein Metabolism in Cells, Mice, and Men
$953,882Henry N Ginsberg · Columbia University Health Sciences · R35 · FY2021 · HL
Phenotyping Genetic Disorders of Hepatic Lipid and Lipoprotein Metabolism in Cells, Mice, and Men
$953,882Henry N Ginsberg · Columbia University Health Sciences · R35 · FY2019 · HL